论文部分内容阅读
目的探讨MAE方案治疗难治性和复发性急性淋巴细胞白血病的疗效。方法予11例难治性和复发性急性淋巴细胞白血病患者MAE方案化疗,并观察其疗效。获得缓解的患者中,有条件者行异基因造血干细胞移植术,无条件者予巩固强化治疗。结果11例患者中,5例完全缓解(CR率45.4%),1例部分缓解(PR率9.1%),总有效率为54.5%,无死亡病例。5例完全缓解的患者中,3例行异基因造血干细胞移,2例获持续缓解。2例行巩固化疗,其中1例仍处缓解期。结论MAE方案治疗难治性和复发性成人急性淋巴细胞白血病是安全、有效的。
Objective To investigate the efficacy of MAE regimen in the treatment of refractory and recurrent acute lymphoblastic leukemia. Methods Eleven patients with refractory or recurrent acute lymphoblastic leukemia were treated with MAE regimen and the curative effect was observed. Among the patients who were relieved, allogeneic hematopoietic stem cell transplantation was performed in those with conditions, and those with unconditional treatment were given intensive treatment. Results Of 11 patients, 5 were completely relieved (CR rate was 45.4%), 1 was partly relieved (PR rate was 9.1%), and the total effective rate was 54.5%. There were no deaths. Three of five patients with complete remission performed allogeneic hematopoietic stem cell transplantation and two patients sustained remission. 2 routine consolidation chemotherapy, of which 1 case still remission. Conclusion The MAE regimen is safe and effective in the treatment of refractory and recurrent adult acute lymphoblastic leukemia.